Baidu
map

AJKD:研究显示低钠浓度透析液对血液透析患者的影响

2012-02-25 MedSci MedSci原创

近日,国际杂志American Journal of Kidney Diseases在线刊登了国外研究人员的最新研究成果“Effect of Lowering Dialysate Sodium Concentration on Interdialytic Weight Gain and Blood Pressure in Patients Undergoing Thrice-Weekly In-c

近日,国际杂志American Journal of Kidney Diseases在线刊登了国外研究人员的最新研究成果“Effect of Lowering Dialysate Sodium Concentration on Interdialytic Weight Gain and Blood Pressure in Patients Undergoing Thrice-Weekly In-center Nocturnal Hemodialysis: A Quality Improvement Study,”,文章中,研究者表示低钠浓度透析液对一周三次夜间血液透析患者的影响。

与传统的血液透析相比,在血液透析行夜间透析的患者在透析间期体重增加(IDWG)明显。

这里选取了15名HD患者来观察低钠浓度透析液对于一周三次夜间透析患者透析间体重增加和血压的影响,给予了先后3次疗程(12周/疗程),每次给予不同钠浓度透析液,分别为A期140 mEq/L、B期136 mEq/L和A+ 140 mEq/L。结果显示,与A期对比,B期患者的IDWG、IDWG%和透析前收缩期血压得到显著降低,分别为0.6 ± 0.6 kg、0.6% ± 0.8%和8.3 ± 14.9 mm Hg;而透析前舒张压、平均动脉压和透析后血压无明显差异(P>0.05);而发生透析过程低血压的发生率是相似的;B期与A期相比,透析前血浆钠离子浓度无差异,而透析后钠离子浓度降低了3.7 ± 1.9 mEq/L (P < 0.05)。

由此可见,低钠浓度透析液可以显著降低一周三次夜间透析患者的IDWG、IDWG%、透析后血浆钠离子浓度和透析前舒张压,而副作用未见增加。

Effect of Lowering Dialysate Sodium Concentration on Interdialytic Weight Gain and Blood Pressure in Patients Undergoing Thrice-Weekly In-center Nocturnal Hemodialysis: A Quality Improvement Study

Jair Munoz Mendoza,Liz Y. Bayes,Sumi Sun, Sheila Doss,Brigitte Schiller,

Background Patients on in-center nocturnal hemodialysis therapy typically experience higher interdialytic weight gain (IDWG) than patients on conventional hemodialysis therapy. We determined the safety and effects of decreasing dialysate sodium concentration on IDWG and blood pressure in patients on thrice-weekly in-center nocturnal hemodialysis therapy. Study Design Quality improvement, pre-post intervention. Settings & Participants 15 participants in a single facility. Quality Improvement Plan Participants underwent three 12-week treatment phases, each with different dialysate sodium concentrations, as follows: phase A, 140 mEq/L; phase B, 136 or 134 mEq/L; and phase A+, 140 mEq/L. Participants were blinded to the exact timing of the intervention. Outcomes IDWG, IDWG/dry weight (IDWG%), and blood pressure. Measurements Outcome data were obtained during the last 2 weeks of each phase and compared with mixed models. The fraction of sessions with adverse events (eg, cramping and hypotension) also was reported. Results IDWG, IDWG%, and predialysis systolic blood pressure decreased significantly by 0.6 ± 0.6 kg, 0.6% ± 0.8%, and 8.3 ± 14.9 mm Hg, respectively, in phase B compared with phase A (P < 0.05 for all comparisons). No differences in predialysis diastolic and mean arterial or postdialysis blood pressures were found (P > 0.05 for all comparisons). The proportion of treatments with intradialytic hypotension was low and similar in each phase (P = 0.9). In phase B compared with phase A, predialysis plasma sodium concentration was unchanged (P > 0.05), whereas postdialysis plasma sodium concentration decreased by 3.7 ± 1.9 mEq/L (P < 0.05). Limitations Modest sample size. Conclusion Decreasing dialysate sodium concentrations in patients undergoing thrice-weekly in-center nocturnal hemodialysis resulted in a clinical and statistically significant decrease in IDWG, IDWG%, postdialysis plasma sodium concentration, and predialysis systolic blood pressure without increasing adverse events. Prolonged exposure to higher than required dialysate sodium concentrations may drive IDWG and counteract some of the purported benefits of “go-slow” (longer session length) hemodialysis.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1262444, encodeId=79b812624449f, content=<a href='/topic/show?id=a57589339a4' target=_blank style='color:#2F92EE;'>#血液透析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89339, encryptionId=a57589339a4, topicName=血液透析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19c567, createdName=habb, createdTime=Sun Feb 26 15:02:00 CST 2012, time=2012-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538246, encodeId=18a41538246e8, content=<a href='/topic/show?id=1258263835a' target=_blank style='color:#2F92EE;'>#低钠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26383, encryptionId=1258263835a, topicName=低钠)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9512951240, createdName=zz12341238, createdTime=Sun Feb 26 15:02:00 CST 2012, time=2012-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544355, encodeId=220815443559e, content=<a href='/topic/show?id=ac3d6549e75' target=_blank style='color:#2F92EE;'>#浓度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65497, encryptionId=ac3d6549e75, topicName=浓度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16b213663040, createdName=12498974m55暂无昵称, createdTime=Sun Feb 26 15:02:00 CST 2012, time=2012-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570560, encodeId=e6c515e056088, content=<a href='/topic/show?id=e53d94835a5' target=_blank style='color:#2F92EE;'>#透析患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94835, encryptionId=e53d94835a5, topicName=透析患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4b0915676167, createdName=ewsr6, createdTime=Sun Feb 26 15:02:00 CST 2012, time=2012-02-26, status=1, ipAttribution=)]
    2012-02-26 habb
  2. [GetPortalCommentsPageByObjectIdResponse(id=1262444, encodeId=79b812624449f, content=<a href='/topic/show?id=a57589339a4' target=_blank style='color:#2F92EE;'>#血液透析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89339, encryptionId=a57589339a4, topicName=血液透析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19c567, createdName=habb, createdTime=Sun Feb 26 15:02:00 CST 2012, time=2012-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538246, encodeId=18a41538246e8, content=<a href='/topic/show?id=1258263835a' target=_blank style='color:#2F92EE;'>#低钠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26383, encryptionId=1258263835a, topicName=低钠)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9512951240, createdName=zz12341238, createdTime=Sun Feb 26 15:02:00 CST 2012, time=2012-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544355, encodeId=220815443559e, content=<a href='/topic/show?id=ac3d6549e75' target=_blank style='color:#2F92EE;'>#浓度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65497, encryptionId=ac3d6549e75, topicName=浓度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16b213663040, createdName=12498974m55暂无昵称, createdTime=Sun Feb 26 15:02:00 CST 2012, time=2012-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570560, encodeId=e6c515e056088, content=<a href='/topic/show?id=e53d94835a5' target=_blank style='color:#2F92EE;'>#透析患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94835, encryptionId=e53d94835a5, topicName=透析患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4b0915676167, createdName=ewsr6, createdTime=Sun Feb 26 15:02:00 CST 2012, time=2012-02-26, status=1, ipAttribution=)]
    2012-02-26 zz12341238
  3. [GetPortalCommentsPageByObjectIdResponse(id=1262444, encodeId=79b812624449f, content=<a href='/topic/show?id=a57589339a4' target=_blank style='color:#2F92EE;'>#血液透析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89339, encryptionId=a57589339a4, topicName=血液透析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19c567, createdName=habb, createdTime=Sun Feb 26 15:02:00 CST 2012, time=2012-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538246, encodeId=18a41538246e8, content=<a href='/topic/show?id=1258263835a' target=_blank style='color:#2F92EE;'>#低钠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26383, encryptionId=1258263835a, topicName=低钠)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9512951240, createdName=zz12341238, createdTime=Sun Feb 26 15:02:00 CST 2012, time=2012-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544355, encodeId=220815443559e, content=<a href='/topic/show?id=ac3d6549e75' target=_blank style='color:#2F92EE;'>#浓度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65497, encryptionId=ac3d6549e75, topicName=浓度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16b213663040, createdName=12498974m55暂无昵称, createdTime=Sun Feb 26 15:02:00 CST 2012, time=2012-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570560, encodeId=e6c515e056088, content=<a href='/topic/show?id=e53d94835a5' target=_blank style='color:#2F92EE;'>#透析患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94835, encryptionId=e53d94835a5, topicName=透析患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4b0915676167, createdName=ewsr6, createdTime=Sun Feb 26 15:02:00 CST 2012, time=2012-02-26, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1262444, encodeId=79b812624449f, content=<a href='/topic/show?id=a57589339a4' target=_blank style='color:#2F92EE;'>#血液透析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89339, encryptionId=a57589339a4, topicName=血液透析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19c567, createdName=habb, createdTime=Sun Feb 26 15:02:00 CST 2012, time=2012-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538246, encodeId=18a41538246e8, content=<a href='/topic/show?id=1258263835a' target=_blank style='color:#2F92EE;'>#低钠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26383, encryptionId=1258263835a, topicName=低钠)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9512951240, createdName=zz12341238, createdTime=Sun Feb 26 15:02:00 CST 2012, time=2012-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544355, encodeId=220815443559e, content=<a href='/topic/show?id=ac3d6549e75' target=_blank style='color:#2F92EE;'>#浓度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65497, encryptionId=ac3d6549e75, topicName=浓度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16b213663040, createdName=12498974m55暂无昵称, createdTime=Sun Feb 26 15:02:00 CST 2012, time=2012-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570560, encodeId=e6c515e056088, content=<a href='/topic/show?id=e53d94835a5' target=_blank style='color:#2F92EE;'>#透析患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94835, encryptionId=e53d94835a5, topicName=透析患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4b0915676167, createdName=ewsr6, createdTime=Sun Feb 26 15:02:00 CST 2012, time=2012-02-26, status=1, ipAttribution=)]
Baidu
map
Baidu
map
Baidu
map